Anavex Life Sciences Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים AVXL

The annual percentage change in earnings per share (ttm) for Anavex Life Sciences (AVXL) reflects a lack of current sales due to the clinical testing stage. The value of 72.60 characterizes this level. This trend is driven by the development of innovative brain cell protection methods and high scientific potential, while the patent strategy ensures global market reach with low production costs for future drugs.
anavex.com - פילוחים אנליטיים ומדדי מפתח (AVXL)

To select assets with a high margin of safety, it is critical to analyze the net profit per share dynamics over a rolling year. This indicator measures the growth rate of EPS TTM, allowing for an assessment of trend sustainability without reporting time lags, which for the biotech company Anavex Life Sciences (AVXL) in the context of dementia therapy development, defines the financial foundation for future capture of the neurodegeneration market through the current state of annual EPS TTM growth.